Unaudited financial results of the Company for the half year ended on September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 0.2 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hemant Surgical Industries reported standalone revenue from operations of Rs 6,426.06 lakhs for H1 FY26 (ended Sep 30, 2025), up about 31% from Rs 4,887.06 lakhs in H1 FY25. However, profit after tax fell sharply to Rs 540.53 lakhs from Rs 813.21 lakhs a year earlier, and profit before tax dropped to Rs 722.32 lakhs from Rs 1,055.53 lakhs, pointing to significant margin compression as raw material costs and finance charges climbed. Basic EPS for the period stood at Rs 4.74 versus Rs 7.79 for the full prior year. During the half year, the company raised Rs 6,152.71 lakhs via a preferential issue of 25.98 lakh equity shares and 20.99 lakh warrants at Rs 197 each, with most of the proceeds yet to be deployed. Consolidated numbers include the newly acquired subsidiary, Solar Opto Medic Pvt Ltd (acquired March 13, 2025).
Strong top-line growth is a positive, but the sharp drop in profit and margins indicates cost pressure that may worry investors in the near term. The Rs 6,152.71 lakh capital raise supports expansion plans but will dilute existing shareholders over time as warrants convert. Stock reaction will likely depend on whether margin recovery is visible in the second half.